Is your antiseptic effective against clinical multidrug-resistant microorganisms? A chlorhexidine digluconate formulation demonstrates efficacy even in lower concentrations by unknown
POSTER PRESENTATION Open Access
Is your antiseptic effective against clinical multidrug-
resistant microorganisms? A chlorhexidine
digluconate formulation demonstrates efficacy even
in lower concentrations
NT Mutters*, F Günther, S Kaiser, T Fries, U Frank
From 3rd International Conference on Prevention and Infection Control (ICPIC 2015)
Geneva, Switzerland. 16-19 June 2015
Introduction
Managing Healthcare-associated Infections (HAI) and
multidrug-resistant Microorganisms (MDRO) is a daily
challenge in hospitals. Universal decolonization by daily
bathing with impregnated cloths can result in a reduc-
tion of HAIs.
Objectives
The objective of this study was to measure the effective-
ness of a Chlorhexidine digluconate (CHG) formulation
against clinical MDRO.
Methods
Gram-negatives were classified as extensively drug-resistant
(XDR-GN) [1]. Additionally, MRSA and VRE isolates were
tested. CHG was tested in concentrations of 20mg/ml,
10mg/ml, and 5mg/ml. Two analyses were performed. (1)
A quantitative suspension test according to European Stan-
dard EN 12353 [2]. Briefly, bactericidal efficacy was deter-
mined without organic load, neutralizations was achieved
by Caso-bouillon and LTHTh. (2) MIC testing procedures
were based on those outlined in the FDA Tentative Final
Monograph. Briefly, a 96 well microtitre plate containing
doubling dilutions of CHG was set up; broth culltures were
standardised to 1x10^8 CFU/mL and added. MIC was
defined as the lowest concentration of CHG at which no
bacterial growth was observed.
Results
The suspension tests showed good susceptibility to CHG
of all strains. Reduction rates were 99.9-100% for all
strains even in lower concentrations. At 15 seconds and
a CHG concentration of 5mg/ml a 99.97% reduction of
XDR P. aeruginosa, a 99.99% reduction of XRD K. pneu-
moniae, and a 99.94% reduction of XDR E. coli could be
demonstrated. The MIC analysis showed efficacy ran-
ging 19.53 to 39.06 µg/ml in XDR P. aeruginosa, 4.88 to
39.06 µg/ml in XDR K. pneumoniae, and 4.88 to
9.77 µg/ml in XDR E. coli. MRSA showed very low
MICs ranging from 1 : 8192 to 1 : 65536; VRE showed
MICs ranging from 1 : 512 to 1 : 2048.
Conclusion
In both analyses, CHG demonstrated an excellent perfor-
mance against MDRO. The results of these clinical isolates
studies and the concentration achieved on patient’s skin
demonstrate a very large safety margin when using this
formulation. Effective decolonization of patients’ skin can
play an important role in reducing risk of HAIs.
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